HeartWare raises $55 million in wake of failed Thoratec merger: Ventricular-assist device maker HeartWare raises $55 million in a private placement of 2.5 million common stock shares at $22 each, announced Aug. 10. The funds will help sustain development efforts for the firm's HeartWare Ventricular Assist System with HVAD pump in the wake of Thoratec's failed bid to acquire the company for $282 million. Thoratec pulled out of the deal July 31 after the Federal Trade Commission raised antitrust concerns (1"The Gray Sheet" Aug. 3, 2009). Headquartered in Sydney, Australia, and Framingham, Mass., HeartWare will use the proceeds from the private placement "for the furtherance of its clinical and commercial roll-out of the HeartWare HVAD and its pipeline of future pumps," the company says in a filing with the Securities and Exchange Commission. The system received CE mark approval in Europe for bridge-to-transplant therapy in January; a 150-patient U.S. trial is ongoing for the same indication (2"The Gray Sheet" Feb. 16, 2009)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul
Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
For the full year, the company now expects tariffs to increase the cost of sales by approximately 1% of revenue, plus or minus 20 basis points. This is lower than the previous estimate of approximately 1.7% of revenue. The updated gross margin guidance for 2025 is 66%-67%, up from 65%-66.5%.
ForSight Robotics is developing a robotic platform to automate cataract and other eye surgeries, aiming to ease surgeon strain and expand access. Backed by $200m in total funding, it's targeting a first human surgery using Oryom by year-end and is in discussions with US FDA.
The US Department of Health and Human Services has proposed cutting Medicare reimbursement for skin substitutes used in chronic wound care by up to 90%. The change aims to address rising costs but could harm patient access and treatment quality, prompting concerns from industry stakeholders.